<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>


HLS Therapeutics Announces Participation at Upcoming Investor Conferences

TORONTO, May 26, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will participate in two upcoming investor conferences in the month of June.

1. Jefferies Virtual Healthcare Conference June 1-4, 2021

  • HLS presents Tuesday June 1, 2021 at 8:30am EDT
  • Listen to the live webcast, click here

2. Raymond James Human Health Innovation Conference June 21-23, 2021

  • HLS presents Wednesday June 23, 2021 at 9:20am EDT
  • Listen to the webcast, click here

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, 416.247.9652, d.mason@hlstherapeutics.com